RWRobyn L. Woods

Robyn L. Woods

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robyn L. Woods has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Colleen J. Thomas

    Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Victoria 3010, Australia

    2 shared publications
  • Sally G. Hood

    Howard Florey Institute, University of Melbourne, Victoria 3010, Australia

    2 shared publications
  • Anke C. Rosenkranz

    Howard Florey Institute, Parkville, Victoria, Australia

    1 shared publication
  • Colin R. Anderson

    Department of Anatomy and Cell Biology, University of Melbourne, Victoria 3010, Australia

    1 shared publication
  • Colleen J Thomas

    Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, Parkville and Baker Medical Research Institute, Prahran, Victoria, Australia

    1 shared publication
  • Evette M. Kairuz

    Howard Florey Institute, University of Melbourne, Victoria, Australia

    1 shared publication

Latest Publications

  • Open Access

    C-type natriuretic peptide (CNP) suppresses plasminogen activator inhibitor-1 (PAI-1) in vivo

    by Evette M. Kairuz, Melissa N. Barber, Colin R. Anderson, Meetali Kanagasundaram, Grant R. Drummond, Robyn L. Woods

    Objective: Elevated vascular plasminogen activator inhibitor-1 (PAI-1) levels are associated with atherosclerosis. In vitro, C-type natriuretic peptide (CNP) has anti-proliferative effects and inhibits the production of PAI-1 in cultured vascular cells. Whether CNP can affect PAI-1 in vivo, particularly in the setting of atherosclerosis, has not been reported. Methods: Using the rabbit carotid arterial collar model of intimal hyperplasia (collar in place for 7 days), PAI-1 protein was compared in normal, vehicle (saline)-collared, and CNP-treated-collared arteries from the same animal. PAI-1 levels were measured by immunohistochemistry and densitometry and by Western blot. CNP was either infused into the peri-arterial space within one collar (10 fmol/h) or infused directly into the arterial lumen under one collar (100 pmol/h). In some rabbits (n=8), superoxide production in collared and normal artery segments was measured in vitro by chemiluminescence. Results: PAI-1 was present throughout the vascular wall. Endothelial PAI-1 was elevated in saline-collared arteries (∼16%, Pn=7 rabbits) compared with normal carotid segments. The collar induced both a neointima that contained PAI-1 and the accumulation of macrophages in the adventitia. Peri-arterial CNP reduced PAI-1 (Pn=8). Peri-arterial CNP treatment did not reduce intimal thickening. Intra-luminal CNP (n=6) reduced endothelial, neointimal and total vessel (Western blot) PAI-1, macrophage accumulation, and intimal thickening (all PConclusions: CNP treatment of collared carotid arteries in vivo for 1 week suppressed endothelial and neointimal PAI-1, independently of intimal thickening. The CNP effects were not via superoxide. This is the first evidence that CNP inhibits activated PAI-1, in vivo.


  • CARDIOPROTECTIVE FUNCTIONS OF ATRIAL NATRIURETIC PEPTIDE AND B‐TYPE NATRIURETIC PEPTIDE: A BRIEF REVIEW

    by Robyn L Woods

    SUMMARY: 1. If one was to design a hormone to protect the heart, it would have a number of features shown by the cardiac natriuretic peptides atrial natriuretic peptide (ANP) and B‐type natriuretic peptide (BNP). These hormones are made in cardiomyocytes and are released into the circulation in response to atrial and ventricular stretch, respectively. Atrial natriuretic peptide and BNP can reduce the preload and after‐load in normal and failing hearts. They reduce blood volume over the short term by sequestering plasma and over the longer term by promoting renal salt and water excretion and by antagonizing the renin–angiotensin–aldosterone system at many levels. Each of these actions affords indirect benefit to a volume‐ or pressure‐threatened heart.2. Recent studies have identified additional modes of action of the natriuretic peptides that may also confer cardioprotective benefits, especially in heart disease. The emerging findings are: (i) that ANP and BNP antagonize the cardiac hypertrophic action of angiotensin II and continue working under conditions where endothelial nitric oxide (NO) function is compromised, such as in the presence of high glucose in diabetes; (ii) they potentiate the bradycardia caused by inhibitory (‘autoprotective’) cardio‐cardiac reflexes; and, furthermore, (iii) BNP can suppress cardiac sympathetic nerve activity in humans, including those with heart failure. Thus, it appears that natriuretic peptides can shift sympathovagal balance in a beneficial direction (away from the sympathetic). The vagal reflex and antihypertrophic actions of the peptides are mediated by particulate guanylyl cyclase (pGC) natriuretic peptide receptors.3. The multiple synergistic actions of the natriuretic peptides make them and their pGC receptors attractive targets for therapy in heart disease. Encouragingly, exogenous natriuretic peptides remain effective even when endogenous peptide levels are raised, as is the case in heart failure. They also remain effective in disease states where other protective mechanisms, such as the NO system, have become ineffective, offering yet further encouragement for the therapeutic use of the natriuretic peptides.


  • Open Access

    Do natriuretic peptides modify arterial baroreflexes in sheep?

    by Colleen J. Thomas, Robyn L. Woods


  • Haemodynamic action of B‐type natriuretic peptide substantially outlasts its plasma half‐life in conscious dogs

    by Colleen J Thomas, Robyn L Woods

    1. The objective of the present study was to determine the plasma half‐life of B‐type natriuretic peptide (BNP) in conscious dogs after intravenous administration and to compare this with its haemodynamic effects. In six chronically instrumented dogs, plasma BNP concentrations were measured under basal conditions, during a constant infusion of canine BNP‐32 (10 pmol/kg per min; 25 min) to steady state and at nominated time points up to 75 min after stopping the infusion. Concomitant, continuous measurements of mean arterial blood pressure (MAP), heart rate (HR), central venous pressure (CVP) and mesenteric blood flow (MBF) were obtained. 2. Baseline plasma BNP levels were 15.0 ± 2.3 fmol/mL and rose approximately 10‐fold to 159 ± 23 fmol/mL after 20–25 min BNP infusion. When the infusion was turned off, plasma BNP levels declined in a biphasic manner, with an initial half‐life of 1.57 ± 0.14 min and a terminal half‐life of 301 ± 85 min. The metabolic clearance rate of BNP was 2.29 ± 0.34 L/min. 3. The infusion of BNP reduced MAP (approximately 10%), CVP (approximately 65%) and MBF (approximately 25%), whereas haematocrit (approximately 4%) and mesenteric vascular resistance (MVR) increased (approximately 40%; all P < 0.05). Plasma BNP levels returned to baseline by 20 min after BNP infusion had been stopped, whereas none of the haemodynamic variables returned to normal by this time. Mean arterial pressure returned to resting levels within 10–15 min after plasma BNP returned to normal. However, CVP, haematocrit and MBF remained substantially below baseline values for more than 20 min after circulating BNP levels had returned to pre‐infusion levels. Of these, only mesenteric vascular changes were returned to baseline within 60 min of plasma BNP levels normalizing. 4. These results demonstrate that the removal of BNP from the canine circulation is rapid, similar to observations made regarding the metabolism of circulating atrial natriuretic peptide in dogs. The half‐life of BNP in dogs was shorter than that in rats, sheep or humans. However, the haemodynamic actions of BNP substantially outlasted its plasma half‐life. Whether this disparity in plasma level and haemodynamic activity of BNP reflects long‐lasting activation of second messenger systems or slow recovery from the hydraulic changes at the capillary level, reflected in the haematocrit and CVP, remains to be answered.


  • Guanylyl Cyclase Receptors Mediate Cardiopulmonary Vagal Reflex Actions of ANP

    by Colleen J. Thomas, Robyn L. Woods

    Atrial natriuretic peptide (ANP) potentiates vagal cardiopulmonary reflexes due to chemosensory (Bezold-Jarisch [B-J] reflex) or mechanosensory (ramp baroreflex) activation. The ANP receptor mediating these actions is unknown. We examined the role of particulate guanylyl-cyclase (pGC) receptors in ANP-induced enhancement of cardiopulmonary vagal reflexes. Cardiopulmonary baroreceptor reflex function was assessed by bradycardic responses to ramp blood pressure rises after rapid intravenous methoxamine (100 μg/kg bolus dose). The B-J reflex was evoked by 3 intravenous doses of serotonin (1 to 10 μg/kg). In conscious, chronically instrumented rats (n=9), these tests were performed on each animal during randomized infusions of rat ANP (150 ng/kg per minute IV), saline (270 μL/h IV), the pGC receptor antagonist HS-142-1 (3 mg/kg IV), or combined HS-142-1+ANP treatment. HS-142-1 alone attenuated normal B-J reflex (by 33±8%, P P <0.05), compared with saline infusion. These ANP effects were completely blocked by HS-142-1, demonstrating that the cardiopulmonary vagal reflex actions of ANP occurred through pGC natriuretic peptide receptors. Additionally, we have provided evidence for the first time that pGC natriuretic peptide receptors are essential for the full expression of the B-J reflex but not for that of cardiopulmonary vagal baroreflexes. This tonic interaction between pGC natriuretic peptide receptors and cardiopulmonary chemosensitive receptors may be important during pathophysiological activation of B-J reflex, such as with myocardial infarction.


  • Acute Antihypertrophic Actions of Bradykinin in the Rat Heart

    by Anke C. Rosenkranz, Sally G. Hood, Robyn L. Woods, Gregory J. Dusting, Rebecca H. Ritchie

    The antihypertrophic action of angiotensin (Ang)-converting enzyme (ACE) inhibitors in the heart is attributed in part to potentiation of bradykinin. Bradykinin prevents hypertrophy of cultured cardiomyocytes by releasing nitric oxide (NO) from endothelial cells, which increases cardiomyocyte guanosine 3′5′-cyclic monophosphate (cyclic GMP). It is unknown whether cyclic GMP is essential for the action of bradykinin, or whether findings in isolated cardiomyocytes apply in whole hearts, in the presence of other cell types and mechanical/dynamic activity. We now examine the contribution of cyclic GMP to the antihypertrophic action of bradykinin in cardiomyocytes and perfused hearts. In adult rat isolated cardiomyocytes cocultured with bovine aortic endothelial cells, the inhibitory action of bradykinin (10 μmol/L) against Ang II (1 μmol/L)–induced [ 3 H]phenylalanine incorporation was abolished by the soluble guanylyl cyclase inhibitor [1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one (10 μmol/L). In Langendorff-perfused rat hearts, Ang II (10 nmol/L)–induced increases in [ 3 H]phenylalanine incorporation and atrial natriuretic peptide mRNA expression were prevented by bradykinin (100 nmol/L), the NO donor sodium nitroprusside (3 μmol/L), and the ACE inhibitor ramiprilat (100 nmol/L). The acute antihypertrophic action of bradykinin was accompanied by increased left ventricular cyclic GMP, and the ramiprilat effect was attenuated by HOE 140 (1 μmol/L, a B 2 -kinin receptor antagonist) or [1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one (100 nmol/L). In conclusion, bradykinin exerts a direct inhibitory action against the acute hypertrophic response to Ang II in rat isolated hearts, and elevation of cardiomyocyte cyclic GMP may be an important antihypertrophic mechanism used by bradykinin and ramiprilat in the heart.


  • Type‐C Natriuretic Peptide Prevents Development Of Experimental Atherosclerosis In Rabbits

    by Tracey A Gaspari, Melissa N Barber, Robyn L Woods, Gregory J Dusting

    SUMMARY: 1. We investigated the effect of local administration of type‐C natriuretic peptide (CNP) on the endothelial dysfunction and development of an atheroma‐like neointima induced by a peri‐arterial collar in rabbits.2. Peri‐arterial collars were placed on both common carotid arteries allowing local treatment of the collared region with either CNP (10 μmol/L) or saline. After 7 days, uncollared (control) and collared sections were taken from both arteries for pharmacological and morphological analysis.3. Application of the collar markedly attenuated (P < 0.05) endothelium‐dependent vasorelaxation induced by acetylcholine (ACh); inhibition of 5‐hydroxytryptamine contraction was 80±5% in control sections compared with 44±4% in collared sections from the same arteries. Local infusion of CNP (10 μmol/L) into the collar restored ACh‐induced vasorelaxation (74±3% from collared arteries + CNP vs 77±2% from control sections from the same arteries).4. Type‐C natriuretic peptide treatment also reduced (P < 0.05) intimal thickening compared with contralateral collared arteries (intima/media ratio 0.06±0.01 vs 0.16±0.01).5. These results provide evidence that locally administered CNP is effective in preventing the endothelial dysfunction and development of a neointima in this model.


  • Atrial, B-type, and C-type natriuretic peptides cause mesenteric vasoconstriction in conscious dogs

    by Robyn L. Woods, Marcus J. M. Jones

    Cardiovascular responses were compared with equimolar infusions of B-type (BNP) and C-type (CNP) with atrial natriuretic peptide (ANP) in conscious, instrumented dogs. On separate days, each natriuretic peptide or vehicle was infused (intravenously) at step-up doses of 2, 5, 10, and 20 pmol ⋅ kg−1⋅ min−1(20 min each dose) to increase circulating levels of the infused peptide from ∼2- to 20-fold. Like ANP, infusions of BNP caused dose-related increases ( P < 0.05) in mesenteric vascular resistance, urine flow, natriuresis, and hematocrit (changes at highest doses were 60 ± 9, 334 ± 113, 313 ± 173, and 12 ± 2%, respectively). BNP also lowered ( P < 0.05) plasma renin activity (−43 ± 11%) and arterial pressure (−10 ± 3%). Effects of BNP were independent of reflex sympathetic activation, since autonomic ganglion blockade did not attenuate the responses. CNP infusions had little effect except to increase ( P < 0.05) mesenteric vascular resistance (27 ± 10%) and plasma ANP (41 ± 7%). Cardiovascular actions of BNP, like those of ANP, counteract the renin-ANG system and may protect the heart by lowering cardiac preload (venous return) and afterload (arterial pressure) while maintaining blood flow to extrasplanchnic regions.